Please try another search
For the three months ended 31 March 2022, Intersect ENT Inc revenues decreased 11% to $21.6M. Net loss increased 44% to $28.8M. Revenues reflect SINUVA segment decrease of 64% to $868K, PROPEL family of products segment decrease of 8% to $18.9M. Higher net loss reflects Research and development increase of 51% to $8.7M (expense), Selling, general and administrative increase of 6% to $25.9M (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 21.57 | 30.67 | 24.4 | 27.35 |
Gross Profit | 13.88 | 22.53 | 19.31 | 19.02 |
Operating Income | -26.67 | -89.51 | -16.88 | -16.07 |
Net Income | -28.8 | -91.15 | -31.85 | -16.6 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 127.39 | 146.87 | 227.97 | 200.86 |
Total Liabilities | 221.42 | 215.94 | 211.75 | 159.23 |
Total Equity | -94.03 | -69.07 | 16.21 | 41.63 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 0 Months |
Cash From Operating Activities | -26.74 | -59.47 | -43.75 | -30.39 |
Cash From Investing Activities | -2.7 | 49.18 | 50.6 | 36.77 |
Cash From Financing Activities | 15.82 | 36.59 | 39.57 | 2.51 |
Net Change in Cash | -13.7 | 25.91 | 46.14 | 8.78 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review